John Hey
Non-Executive Chairman
life sciencess
Bilcare Research
Andorra
Biography
ader, managing preclinical discovery, lead optimization, early development activities, and strategic planning for over 50 scientists. Dr. Hey has a proven record of clinical development of new chemical entities (NCEs) in multiple therapeutic areas, and has been directly responsible for discovery and development of over 20 NCEs, including several that have advanced to NDA stage and approval. Dr. Hey also had additional direct experience supporting Phase 3 and Phase 4 programs for Schering-Plough’s respiratory disease franchise portfolio, including Claritin® /Clarinex®, Asmanex® and Nasonex®. Dr. Hey holds a Ph.D. in Pharmacology from the University of Oklahoma H
Research Interest
ader, managing preclinical discovery, lead optimization, early development activities, and strategic planning for over 50 scientists. Dr. Hey has a proven record of clinical development of new chemical entities (NCEs) in multiple therapeutic areas, and has been directly responsible for discovery and development of over 20 NCEs, including several that have advanced to NDA stage and approval. Dr. Hey also had additional direct experience supporting Phase 3 and Phase 4 programs for Schering-Plough’s respiratory disease franchise portfolio, including Claritin® /Clarinex®, Asmanex® and Nasonex®. Dr. Hey holds a Ph.D. in Pharmacology from the University of Oklahoma H
